Chronic Obstructive Pulmonary Disease Is Associated With Decreased Quality of Life in Bronchiectasis Patients: Findings From the KMBARC Registry

Kim, Sang Hyuk; Kim, Chang-Hwan; Jeong, Ina; Lee, Seung Jun; Kim, Tae Hyung; Lee, Chang Youl; Oh, Yeon‐Mok; Lee, Hyun; Kim, Youlim

doi:10.3389/fmed.2021.722124

Cited by 8 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COPD and bronchiectasis frequently co-exist in patients, so that 54.3% of COPD patients have reported to have bronchiectatic features [ 56 ]. Among bronchiectasis patients, the prevalence of COPD ranged (27% to 69%) in previous studies [ 9 , 56 , 57 ]. These bronchiectasis and COPD overlap syndrome (BCOS) patients have shown to have poorer outcomes, including frequent exacerbation, lower lung function, increased mucus production, and increased mortality [ 11 , 12 , 56 ].…”

Section: Pharmacologic Treatmentsmentioning

confidence: 91%

Exacerbation Prevention and Management of Bronchiectasis

Choi¹

2023

Tuberc Respir Dis

View full text Add to dashboard Cite

Bronchiectasis, which is characterized by irreversibly damaged and dilated bronchi, causes significant symptoms, poor quality of life, and increased economic burden and mortality rates. Despite its increasing prevalence and clinical significance, bronchiectasis was previously regarded as an orphan disease, and ideal treatment of this disease has been poorly understood. The European Respiratory Society and British Thoracic Society have recently published guidelines to assist physicians in the clinical field. Guidelines and reports suggest comprehensive management that includes both non-pharmacological and pharmacological treatment. Physiotherapy and pulmonary rehabilitation are two of the most important non-pharmacologic therapies in bronchiectasis patients; long-term inhaled antibiotics and macrolide therapy have gained significant evidence in reducing exacerbation risk in frequent exacerbators. In this review, we summarize recent updates on bronchiectasis treatment to prevent exacerbation and manage clinical deterioration.

show abstract

Section: Pharmacologic Treatmentsmentioning

confidence: 91%

Exacerbation Prevention and Management of Bronchiectasis

Choi¹

2023

Tuberc Respir Dis

View full text Add to dashboard Cite

show abstract

“…Some disease entities traditionally regarded as diseases distinguishable from COPD may now be included as a subtype of COPD. logical diagnosis (abnormal dilatation of the bronchi), characterized by cough, sputum production, and recurrent respiratory infections that overlap with other airway diseases [11][12][13] . The overlap between bronchiectasis and COPD is very common.…”

Section: Proposed Taxonomy For Copdmentioning

confidence: 99%

Proposed Etiotypes for Chronic Obstructive Pulmonary Disease: Controversial Issues

Kim,

Moon,

Min

et al. 2024

Tuberc Respir Dis

Self Cite

View full text Add to dashboard Cite

The 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) revised the definition of chronic obstructive pulmonary disease (COPD) to broadly include a variety of etiologies. A new taxonomy, composed of etiotypes, aims to highlight the heterogeneity in causes and pathogenesis of COPD, allowing more personalized management strategies and emphasizing the need for targeted research to understand and manage COPD better. However, controversy arises with including some diseases under the umbrella term of COPD, as their clinical presentations and treatments differ from classical COPD, which is smoking-related. COPD due to infection (COPD-I) and COPD due to environmental exposure (COPD-P) are classifications within the new taxonomy. Some disease entities in these categories show distinct clinical features and may not benefit from conventional COPD treatments, raising questions about their classification as COPD subtypes. There is also controversy regarding whether bronchiectasis with airflow limitations should be classified as an etiotype of COPD. This article discusses controversial issues associated with the proposed etiotypes for COPD in terms of COPD-I, Controversial Issues 1: Bronchiectasis with Airflow LimitationBronchiectasis is a disease entity of clinical and radio-COPD-P, and bronchiectasis. While the updated COPD definition by GOLD 2023 is a major step towards recognizing the disease's complexity, it also raises questions about the classification of related respiratory conditions. This highlights the need for further research to improve our understanding and approach to COPD management.

show abstract